European organizations strongly in favor of gender-neutral HPV vaccination

  • Joura EA & al.
  • Eur J Cancer
  • 1 Jun 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The European Society of Gynaecologic Oncology (ESGO) and the European Federation for Colposcopy (EFC) support gender-neutral human papillomavirus (HPV) vaccination programs for children and young adolescents and a catch-up program for young adults.

Key points

  • Clinical efficacy has been demonstrated against HPV-related cervical, vulvovaginal, and anal precancer and invasive cervical cancer.
  • Vaccination programs should be gender-neutral to improve coverage, and target individuals of prepubertal age groups that give optimal immunologic response and decrease the likelihood of HPV positivity at the time of vaccination.
  • A catch-up program for young adults improves effectiveness.
  • The vaccines are also effective in sexually active individuals with previous but cleared infections. Vaccination in addition to local conservative treatment of HPV-related disease reduces recurrent or subsequent HPV-related disease.
  • School-based programs or other well-organized public health structures are more effective and ensure equity compared with opportunistic vaccination.
  • 3 doses are recommended in individuals aged >15 years (2 doses in those aged
  • HPV screening and vaccination are complementary preventive strategies but are often implemented as separate and noncoordinated programs; combining vaccination and screening with HPV testing appears to be the most effective preventive approach.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit